Brief

On July 2024, the French National Agency for the Safety of Medicines and Health Products (ANSM) mobilized to address a complex situation related to a risk of quetiapine shortage. The agency has been actively working with laboratories and healthcare professionals to cover patient needs, including recalling stock, activating solidarity mechanisms, and identifying alternative treatments, resulting in the distribution of nearly 30,000 equivalent monthly treatments.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies